ClinicalTrials.gg

Program

PEP08

A development code.

Its studies are led by PharmaEngine.

Furthest: phase 1, since May 7, 20251 company-led study, 1 open or runningNext primary completion: Dec 2027 (phase 1)

Who develops it

Each company that leads studies of it, as its sponsor page counts them.

CompanyStudies it leadsFurthest phaseFirst studyNext primary completion
PharmaEngine11 open or runningphase 1since May 7, 2025May 7, 2025Dec 2027phase 1 · NCT06973863

History and what’s ahead

From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.

  1. May 7, 2025First study: phase 1 study in Advanced Solid TumorFirst studyNCT06973863 · 40 planned · Australia, Taiwan

Ahead

  1. Dec 2027Primary completion: phase 1 study in Advanced Solid TumorNCT06973863

TargetBeta

PRMT5 →read by rule
“PEP08 is an oral, potent, MTA-cooperative PRMT5 inhibitor.”study text, by rule · the study

Other programs on PRMT5

ProgramCompanyFurthest phaseStudies
navlimetostatBristol-Myers Squibbphase 310
PRMT5 Inhibitor AZD3470AstraZenecaphase 22
JBI-778rulejubilant-therapeutics-india-limitedphase 22
PRMT5 Inhibitor TNG456ruletango-therapeutics-incphase 21
PRMT5 Inhibitor BAY 3713372ruleBayerphase 21
onametostatruleJohnson & Johnsonphase 12
PRMT5 Inhibitor SH3765ruleNanjing Sanhome Pharmaceuticalphase 12
PRMT5 Inhibitor BGB-58067ruleBeOne Medicinesphase 12
PRMT5 Inhibitor IDE892ruleideaya-biosciencesphase 11

Studies

All 1 led by companies developing it, newest first. Each opens its study page.

StudyPhaseStatusPrimary completionSize
NCT06973863Advanced Solid Tumor · Australia, Taiwan1RecruitingDec 202740

How it is read

Names in the registry

  • “PEP08”, 1 entry

Codes read as this program: PEP08.

Conditions, from the studies’ own filings

    First seen by our ledger Nov 13, 2026.

    What this can’t show

    • Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
    • Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
    • Primary completion dates are the sponsors’ estimates and often move.
    • A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.